Project Grant K08HL173643
Award Date
6/1/24
Completion Date
5/31/29
Dollars Obligated
$172K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on characterizing the role of the alternative complement pathway in the pathogenesis of acute chest syndrome (ACS) in sickle cell disease (SCD). The key objectives are to: 1) define the mechanisms by which complement contributes to the development of ACS using novel preclinical models, microfluidics, and in vitro assays; 2) characterize...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $608,126 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The project aims to (1) define the relationship between common SCD adverse clinical outcomes and single-cell biochemical and mechanical properties, (2) determine the relationship between treatment responses...
This federal Project Grant award of $156,340.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Connecticut Children's Medical Center. The grant supports the development and testing of a communication-enhancement intervention for healthcare providers to improve health outcomes in pediatric sickle cell disease patients. Key research activities include conducting mixed methods research to refine the intervention, promoting the uptake of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $797,130 to The Children's Hospital of Philadelphia (CHOP) from September 2024 to June 2028. The project aims to implement and evaluate the real-world effectiveness of "single maintenance and reliever therapy" (SMART) for managing moderate-to-severe childhood asthma in a predominantly Black pediatric population. The study uses a...
This $265,347 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc. to assess red blood cell sickling in patients with sickle cell disease. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system that can be used to monitor patient condition and treatment response, especially for drugs affecting...
The National Heart Lung and Blood Institute (NHLBI) awarded a $1,829,965.51 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Children's Research Institute, located in Washington, D.C. The grant supports a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the use of intravenous citrulline as a treatment for vaso-occlusive crisis in sickle cell disease patients. The trial aims to determine if citrulline administration can shorten...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $827,753.90 to Bloodworks, a non-profit organization in Seattle, to conduct research on oxidative cysteine modification by thiol isomerases and its role in vaso-occlusive events in sickle cell disease. The research aims to mechanistically examine how protein disulfide isomerase (PDI) senses the redox environment in sickle cell disease, catalyze electron...